Abstract. Neuroblastoma is a childhood cancer originating from embryonic neural crest cells. Amplification of the proto-oncogene N-myc, seen in ~30% of neuroblastoma tumors, is a marker for poor prognosis. Recently discovered small regulatory RNAs, microRNAs (miRNAs), are implicated in cancers, including neuroblastoma. miRNAs downregulate the expression of genes by binding to the 3'-untranslated regions (3'-UTRs), thereby inhibiting translation or inducing degradation of cognate mRNAs. Our study sought to identify miRNAs that regulate N-myc expression and thereby malignancy in neuroblastoma. miRNAs whose expression negatively correlates with N-myc expression were identified from a miRNA microarray of 4 N-myc-amplified neuroblastoma cell lines. Three of these miRNAs (miR-17, miR-20a and miR-18a) belong to the miR-17-92 cluster, previously shown to be upregulated by N-myc. qPCR validation of these miRNAs in a larger panel of cell lines revealed that levels of miR-17 were inversely proportional to N-myc mRNA amounts in the N-myc-amplified cell lines. Notably, miR-17 also downregulated N-myc protein synthesis in the N-myc-amplified cells, thereby generating a negative feedback regulatory loop between the proto-oncogene and this miRNA. Moreover, the neuronal-specific RNA-binding protein HuD (ELAVL4), which regulates the processing/stability of N-myc mRNA, competes with miR-17 for a binding site in the 3'-UTR of N-myc. Thus, N-myc levels appear to be modulated by the antagonistic interactions of both miR-17, as a negative regulator, and HuD, as a positive regulator, providing further evidence of the complex cellular control mechanisms of this oncogene in N-myc-amplified neuroblastoma cells.
Introduction
Neuroblastoma (NB) is the most common extracranial solid tumor in children. One of the major biological factors related to poor patient survival is amplification of the N-myc gene, which is seen in ~30% of cases (1) . This proto-oncogene encodes a basic helix-loop-helix transcription factor that binds to E-box elements (2) in the numerous genes it regulates. Since the majority of neuroblastoma patients with overexpression of N-myc have a lower survival rate, defining novel pathways that regulate its expression is critical for developing new therapeutic approaches to better treat this enigmatic cancer.
MicroRNAs (miRNAs) are small (~21 nucleotides) non-coding regulatory RNAs that downregulate the expression of mRNAs either by inhibiting their translation and/or facilitating the degradation of the cognate mRNA (3) . Several recent studies have reported a role for miRNAs in targeting or being targets of N-myc in neuroblastoma (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Of particular interest has been the relationship between N-myc expression and members of the miR-17-92 miRNA cluster, a polycistronic cluster on chromosome 13q31.32 that gives rise to 6 mature miRNAs (miR-17, miR-18a, miR-19a, miR-20a and miR-92-1). Several previous studies in human neuroblastoma cell lines have shown that the expression levels of the miR-17-92 cluster members are directly correlated with N-myc amplification and that N-myc binds to E-boxes to increase the transcription of this gene cluster (5, 16) . Likewise, miR-17-92 overexpression is associated with increased tumorigenicity in numerous types of cancer, including neuroblastoma (17) .
Our previous studies have shown that another RNA-binding element also plays an important role in the amplification and overexpression of N-myc: the neuronal-specific RNA binding protein HuD (ELAVL4). This protein is involved in the splicing and stabilization of N-myc mRNA (18) (19) (20) , and its decreased expression (consequent to loss of the short arm of chromosome #1) leads to N-myc amplification in neuroblastoma. Conversely, re-introduction of HuD genes removes the selection pressure, resulting in loss of N-myc genes (20) .
In the present study, we demonstrate that miR-17, a member of the miR-17-92 cluster, is induced by N-myc and reciprocally binds to the N-myc 3'-untranslated region (3'-UTR) to downregulate its expression, creating a negative-feedback loop in N-myc-amplified neuroblastoma cell lines. Moreover, the 3'-UTR region to which miR-17 binds contains an overlapping binding site for HuD and the miRNA and this RNA-binding protein compete for binding to this site. This competition may be exacerbated in N-myc-amplified neuroblastoma cells, which lack one copy of the HuD gene. A possible consequence of this imbalance is a heightened selection pressure resulting in the extremely high levels of N-myc gene amplification seen in neuroblastoma as well as the increased malignancy and decreased differentiation in N-myc-amplified neuroblastoma cells.
Materials and methods
Cell culture. All cell lines were maintained as previously described (21) . Thirteen human neuroblastoma clonal cell lines or enriched populations were used in these studies: N-myc-amplified (SK-N-BE(1)n, LA1-55n, KCN-83n, BE(2)-M17V, SK-N-LD, SK-N-HM, BE(2)-C and LA1-5s), and N-myc non-amplified (SH-SY5Y, SMS-LHN, CB-JMN, SH-EP1 and SMS-KCNs).
miRNA microarray. miRNAs were isolated using mirVana™ miRNA Isolation kits (Ambion, Austin, TX, USA). Processing and initial analysis of miRNA expression levels were carried out by LC Sciences (Houston, TX, USA). The correlation between N-myc RNA and miRNA expression levels was assessed by linear regression analysis.
Quantitative real-time RT-PCR. cDNA for miRNAs were synthesized using the TaqMan ® MicroRNA Reverse Transcription kit. miRNA-specific primers and miRNAs were quantified using TaqMan assays (Applied Biosystems, Foster City, CA, USA) by the comparative ΔΔC t method. Expression levels of miRNAs were normalized to U6 and expressed as a fold-change compared to the levels of the same sample of SH-SY5Y cells.
Western blot analysis. western blot analysis of proteins was performed as previously described (21) . Primary antibodies used were rabbit anti-N-myc [(C-19), (SC-791)] (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and mouse anti-actin [(AC-74), (076K4762)] (Invitrogen Corp., Carlsbad, CA, USA).
Transfections and infections. miRNA inhibitors for miR-17 and control oligos (100 nM) (Ambion) were transiently transfected into SK-N-LD cells using Lipofectamine 2000 (Invitrogen Corp.) according to the manufacturer's instructions. Lentivirus constructs containing the miR-17-92 cluster and controls were purchased from SBI Biosciences (Mountain View, CA, USA) and used to infect SK-N-LD and CB-JMN cells at a multiplicity of infection of 10, according to the manufacturer's instructions. Resulting populations were either used directly or cloned using cloning cylinders.
Luciferase and β-galactosidase assays. The 3'-UTR of N-myc (880 bp) was PCR-amplified (primers available upon request) and cloned into pMIR-Luciferase reporter plasmid (Ambion) using T4-ligase (Promega, Madison, wI, USA). The sequences of the inserts were confirmed (GENEWIZ, South Plainfield, NJ, USA).
SK-N-LD cells were co-transfected in quadruplicate with either pMIR-Luciferase-N-myc-UTR or pMIR-REPORT-Luciferase (Luciferase vector) and pMIR-REPORT-β-gal (Ambion) using Lipofectamine 2000.
After 24 h, half of each of the co-transfected populations were treated with 100 nM of either the miR-17 inhibitor or a non-specific control oligo (both from Ambion). Twenty-four hours thereafter luciferase and β-gal activities were assessed (Promega). Luciferase activity was normalized to β-gal and expressed as a fold-change in the miR-17-inhibitor-treated cells compared to the control-treated cells for both the pMIR-Luciferase-full-N-myc 3'-UTR and the vector transfectants.
Colony-forming efficiency. Colony-forming efficiencies in soft agar were assessed as previously described (21) . Mean colony-forming efficiency (CFE; the number of colonies divided by the cell inoculum x 100) was determined in quadruplicate in 3 independent experiments.
Gel mobility shift assays (GMSAs).
The pCRII-SNM plasmid, containing 399 nt at the 3'-end of the N-myc 3'-UTR (19) was linearized and used to generate radioactive probes for gel shift assays using the MAXIscript T7 in vitro transcription kit (Ambion) and 32 P-UTP (PerkinElmer, Inc., waltham, MA, USA). The probes generated were treated with DNase and purified using a MEGAclear kit (both from Ambion).
HuD and HuC proteins were expressed and purified as previously described (19) . Bacterial lysates containing either HuD or HuC protein were mixed with the N-myc 3'-UTR probe (~10,000 cpm) and incubated for 20 min at room temperature. In competition experiments, the probe was pre-mixed in annealing buffer (19) with either mature miR-17 RNA oligo (8, 40 or 80 pmol) or non-specific RNA oligo (40 pmol) (sequences available upon request) (Dharmacon Inc., Chicago, IL, USA), denatured at 95̊C for 5 min and cooled to room temperature before use. RNA-protein complexes were resolved by electrophoresis through 3.2% non-denaturing polyacrylamide gels and exposed to Kodak XAR film overnight at -80̊C.
Results
Inverse relationship between N-myc mRNA and miR-17-92 cluster expression. To identify miRNAs that regulate N-myc, we analyzed the expression of miRNAs in 4 human neuroblastoma cell lines with varying degrees of N-myc amplification using an miRNA microarray. The 4 cell lines had N-myc relative mRNA levels (compared to the non-amplified SH-SY5Y neuroblastoma cell line) ranging from 16-to 183-fold. The levels of each miRNA in the 4 lines were compared to the N-myc levels by linear regression analysis, and ranked in descending order according to the R 2 value. Notably, from this analysis, we found a highly inverse correlation between the expression level of N-myc and most of the miR-17-92 cluster members (Table I) . Additional qRT-PCR analysis for 3 of the miRNAs (miR-17, miR-20a and miR-18a) with a larger set (n=13) of neuroblastoma cell lines clearly revealed that all 3 miRNAs were significantly higher in the N-myc-amplified group (n=8) compared to the N-myc-non-amplified group (n=6) (data not shown) consistent with previous findings. Notably, as predicted by the microarray data (Table I) , the qRT-PCR data ascertained that the inverse relationship between N-myc expression and miR-17 levels was highly significant (R 2 =0.98; P<0.001) (Fig. 1A) . However, the inverse relationship was not significant for miR-20a and miR-18a in the N-myc-amplified cells. Further studies were undertaken to investigate whether the inverse correlation between miR-17 and N-myc levels is due to the downregulation of N-myc by miR-17.
N-myc 3'-UTR has miR-17 regulatory sites.
Sequence analysis revealed a complementary binding site for miR-17 within the 3'-UTR of N-myc mRNA (Fig. 1B) , making the oncogene a predicted target of miR-17 (www.microrna. org and www.mirbase.org). To determine whether N-myc mRNA is a target of miR-17, the N-myc full length 3'-UTR was cloned into a luciferase reporter gene and this construct (Luciferase-N-myc-UTR) or the Luciferase vector (control) was transfected into the SK-N-LD N-myc-amplified cell line. when each of these transfectants was treated with the miR-17 inhibitor, the miR-17 levels decreased significantly (3.3-fold; P<0.05) (Fig. 1C) compared to the control oligo transfectants. This decrease in miR-17 resulted in a significant 1.6-fold (P<0.01) increase in luciferase activity in cells expressing the Luciferase-N-myc-UTR construct, but had no effect on the luciferase activity in the Luciferase Table I . Inverse correlation between N-myc overexpression and levels of miR-17-92 cluster members. vector-transfectants (Fig. 1D) . Thus, the binding site of miR-17 in N-myc appears to be functional.
Cell lines
------------------------------------------------------------------------------------------------------------------------------------------------------------- mRNA/miRNA BE(2)-M17 BE(2)-C SK-N-BE(1)n SK-N-
Alteration of miR-17 expression inversely affects N-myc expression.
To confirm the direct regulation of N-myc expression by miR-17, a specific inhibitor for miR-17 was transiently transfected into N-myc-amplified SK-N-LD cells. miR-17 levels were decreased 33.3-fold (P<0.01) (Fig. 1E) . Consequently, N-myc mRNA and protein levels in the inhibitor-transfectants were significantly increased 2.1-fold (P<0.01) and 1.5-fold (P<0.02), respectively, compared to the control cells (Fig. 1E) . Since the expression levels of the homolog miRNAs miR-18a and miR-20a remained unaltered (data not shown), these decreases in N-myc appear to be the result of the specific decrease of miR-17. However, transfection of the miR-17 inhibitor into an N-myc-non-amplified cell line SH-SY5Y did not alter the levels of N-myc mRNA or the protein, suggesting this regulation is not seen in N-myc-non-amplified cells (data not shown).
In converse experiments, levels of miR-17 were increased in SK-N-LD cells by stable infection with a miR-17-92-overexpressing cassette in a lentiviral vector. These infected cell populations had 4.8-fold (P<0.03) higher miR-17 levels compared to the vector-infected control cells (Fig. 2A) . N-myc mRNA levels in the miR-17-92-overexpressing cells decreased significantly 1.7-fold (P<0.02) compared to the control (Fig. 2B) . Collectively, these observations suggest that miR-17 regulates N-myc expression in N-myc-amplified human neuroblastoma cells.
Overexpression of miR-17-92 increases tumorigenicity.
miR-17-92 overexpression is associated with increased tumorigenicity in numerous types of cancer. To assess whether elevated levels of miR-17-92 likewise contributed to increased tumorigenicity of N-myc-amplified cell lines, we stably infected the lentiviral miR-17-92 cassette into a non-amplified cell line, CB-JMN. Two miR-17-92-infected clones with average increases in miR-17 of 7.0-fold (P<0.001) (Fig. 3A) were tested for malignant potential. These infectants had colony-forming efficiencies in soft agar of 17.4 and 18.0%. By contrast, those of the control clones were 4.4 and 5.1% (Fig. 3B) . Thus, increased expression of miR-17-92 appears to be responsible, at least in part, for the increased malignant potential and/or aggressiveness of N-myc-amplified tumors.
Regulation of N-myc by HuD and miR-17.
Previous studies in our laboratory and others have shown that the neuronal-specific RNA-binding protein HuD (ELAVL4) is involved in stabilizing the N-myc mRNA transcript by binding to the AU-rich elements in its 3'-UTR (18) (19) (20) . Since miR-17 binds to the 3'-UTR, but destabilizes the mRNA, we examined the location of the proposed binding sites of both regulators. Notably, the binding sites overlap (Fig. 4A) . To assess whether these 2 regulators compete for binding to the N-myc 3'-UTR, gel shift assays were performed. As shown in Fig. 4B , binding of the recombinant HuD protein to a radio-labeled 399-bp region from the N-myc 3'-UTR containing the 2 putative binding sites protects it from degradation by endogenous bacterial RNases, resulting in an RNA-protein complex that migrates more slowly through the gel (Fig. 4B, lanes 2 and 3) . Notably, prior incubation of the N-myc probe with increasing amounts of miR-17 decreased in a dose-dependent manner the amount of HuD-N-myc complex (Fig. 4B, lanes 4-6) . Formation of the HuD-mRNA complex was not abrogated by preincubation with non-specific RNA oligonucleotides (Fig. 4B, lane 7) or with miR-17 pre-annealed to its antisense sequence (Fig. 4B, lane 8) and was not noted after substitution of HuC, a closely related Hu protein, for HuD (Fig. 4B, lane 9) or pre-incubation of the HuD lysate with cold N-myc 3'-UTR prior to the addition of labeled N-myc 3'-UTR (Fig. 4B, lane 10) . This experiment was repeated with a second, shorter piece (124 bp) of the N-myc 3'-UTR with the same results (data not shown). Thus, the neuronal-specific RNA-binding protein HuD and miR-17 appear to compete for adjacent overlapping binding sites in the 3'-UTR of N-myc, exerting antagonistic effects on N-myc mRNA stability and subsequent protein expression.
Discussion
In the present study, we identified an interaction between miR-17 and HuD, two molecules involved in the regulation of N-myc expression. Several studies have identified miRNAs that correlate with N-myc expression in neuroblastoma cell lines and tumors (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) 22) . Many of these studies revealed that the expression of the miR-17-92 cluster is: i) higher in N-myc-amplified cells (5, 16, 22) ; and ii) regulated by N-myc (5,16), as we also observed in our panel of cells. This cluster, also known as oncomiR-1, has been shown to influence tumorigenicity in many forms of cancer (17) . Schulte et al (22) noted an association between high miR-17-92 levels and an unfavorable outcome in children with neuroblastoma. Moreover, in the present study, increased expression of miR-17-92 increased the tumorigenic potential of an N-myc-non-amplified cell line. Therefore, the aggressive behavior of neuroblastoma tumors with N-myc amplification could be mediated, at least in part, by downregulation of target tumor suppressor/antiproliferative/apoptotic genes (17) consequent to increased levels of miR-17-92.
The negative correlation of N-myc and miR-17 levels in N-myc-amplified neuroblastoma cell lines revealed the existence of a negative feedback loop between N-myc and miR-17. Notably, this relationship was not observed in N-myc-non-amplified cell lines. Why is this negative regulation observed only in N-myc-amplified cell lines? Our previous studies have shown that HuD binds and stabilizes the N-myc transcript (19) . N-myc-amplified cells have lower levels of HuD compared to N-myc-non-amplified cells as a consequence of the loss of one HuD allele with the 1p deletion invariably accompanying N-myc amplification (20) . In non-amplified cells with 2 HuD alleles, HuD protein amounts appear sufficient to block the common binding site and ensure adequate levels of N-myc translation. By contrast, lower levels of HuD may allow increased access to and promote N-myc mRNA degradation by miR-17, leading to N-myc levels too low to sustain viability. This effect may in turn select for cells that have amplified N-myc, as proposed by Grandinetti et al (20) . Overcompensation, leading to excess N-myc RNA and protein, may further increase the amount of miR-17, leading subsequently to both a greater imbalance between the 2 regulators and to greater malignancy. Thus, our findings concerning the interactions between miR-17, HuD and N-myc provided one explanation for the very high levels of N-myc gene amplification found in neuroblastoma.
Increased levels of the oncogenic miR-17-92 cluster, and in particular miR-17, in N-myc-amplified tumors could be a major mediator of their aggressive nature. In addition, the negative feedback regulatory mechanism between N-myc and miR-17 could be an important regulator of cell fate (proliferation vs. apoptosis) in normal as well as in malignant neuroblasts. A similar negative feedback regulatory mechanism has been observed between c-myc and miR-17-92, in which upregulation of the miR-17-92 cluster results in downregulation of E2F (23) . Greater knowledge of the complex interactions between miR-17-92, HuD and N-myc could lead to better understanding of the regulation of N-myc expression and to the discovery of additional drugs or therapeutic approaches for the more effective treatment of N-myc-amplified cancers.
